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Our aim in this study was to compare the efficiency of 25G versus 22G needles in diagnosing solid pancreatic
lesions by EUS-FNA. We performed a systematic review and meta-analysis. Studies were identified in five
databases using an extensive search strategy. Only randomized trials comparing 22G and 25G needles were
included. The results were analyzed by fixed and random effects. A total of 504 studies were found in the
search, among which 4 randomized studies were selected for inclusion in the analysis. A total of 462 patients
were evaluated (233: 25G needle/229: 22G needle). The diagnostic sensitivity was 93% for the 25G needle
and 91% for the 22G needle. The specificity of the 25G needle was 87%, and that of the 22G needle was 83%.
The positive likelihood ratio was 4.57 for the 25G needle and 4.26 for the 22G needle. The area under the sROC
curve for the 25G needle was 0.9705, and it was 0.9795 for the 22G needle, with no statistically significant
difference between them (p=0.497). Based on randomized studies, this meta-analysis did not demonstrate
a significant difference between the 22G and 25G needles used during EUS-FNA in the diagnosis of solid
pancreatic lesions.
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’ INTRODUCTION
The most common etiology of solid pancreatic masses is
adenocarcinoma, responsible for 85 to 95% of cases (1).
Computed tomography (CT) and magnetic resonance imag-
ing (MRI) are the best options for the initial evaluation of
these lesions, as they have the ability to detect the presence
of distant metastases and affected adjacent lymph nodes.
However, in a prospective randomized trial comparing endo-
scopic ultrasound (EUS) and CT for the diagnosis of pan-
creatic cancer, DeWitt et al. confirmed that CT is less sensitive
in the diagnosis of pancreatic cancer and is equivalent to EUS
when evaluating lymph node staging of the disease (2).
EUS is currently considered the most reliable and accurate
method for the detection and diagnosis of pancreatic masses.
The reported sensitivity of EUS in the detection of pancreatic
cancer is between 94% and 100%. Compared with CT, EUS
can detect up to 14% of pancreatic tumors that are not visu-
alized by CT, especially tumors that are smaller than 20 mm,
which are associated with higher rates of diagnostic failure
by MRI and CT. Thus, EUS has greater test sensitivity and
accuracy (3).
EUS-guided fine-needle aspiration has progressed in
relation to its use in studying pancreatic masses based on
the ability to safely collect material for cytological and/or
anatomopathological analysis with a low complication
risk of 0.5 to 2%. The main risks are bleeding and acute
pancreatitis (4).
To standardize the EUS fine-needle aspiration (EUS-FNA)
procedure, Bang et al. have proposed the following algorithm
for needle selection: 25 Gauge (G) needles for transduodenal
EUS-FNA, 22G or 25G needles for other punctures, 19G flexible
needles for transduodenal interventions and standard 19G
needles for other access routes (5).
Currently, EUS-FNA needles are available as 19G, 22G
and 25G needles (6), with an estimated diagnostic sensitivity
of 85-93% (7). The 25G needles are malleable, not interfering
with the torque of the device, but they are less likely to
aspirate a suitable quantity of material for anatomopatholo-
gical analysis. In general, studies have reported good results
using the 22G needle (8), but there is no evidence to date
of its high scientific value to prove its superiority over the
25G needle (9).DOI: 10.6061/clinics/2018/e261
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The decision to use a specific needle gauge involves the
associated risks and benefits. The greater the caliber of the
needle, the greater the risk of post-puncture bleeding and
the greater the chance of obtaining aspirated blood, which
may compromise the quality of the sample, reducing its diag-
nostic value (10).
A smaller needle is technically easier to handle within
the device, especially in anatomical areas where the position
of the endoscope has not been optimized, such as in the
duodenum where the head of the pancreas is examined.
The 25G needle, because of its flexibility, may present
benefits compared with larger needles used for EUS-FNA
at more difficult access sites, such as the pancreatic head,
uncinate process and proximal region of the bile duct (11).
For example, one study reported a failure to puncture in
33% of cases with lesions located at the uncinate process (12).
Thus, most studies compare only 22G and 25G needles, but
there is still no clear evidence of the superiority of one needle
over the other.
We have identified several studies on EUS-guided fine-
needle aspiration and methods for its improvement. These
studies have answered several questions, but there is no
strong evidence to date regarding which needle is best.
The objective of this study was to compare the success
rates of 22G and 25G needles in diagnosing the malignancy
of solid pancreatic lesions when performing EUS-FNA.
’ MATERIALS AND METHODS
Protocol and registration
A protocol specifying the eligibility criteria and methods of
analysis for the studies included in this systematic review
and meta-analysis was established and documented prior
to the start of this review, and it can be accessed at http://
www.crd.york.ac.uk/PROSPERO with the registration num-
ber CRD42016046810.
Eligibility criteria
Types of studies: Randomized trials comparing the use of
22G and 25G needles for EUS-FNA of solid pancreatic lesions
were included.
Types of participants: Patients with solid pancreatic lesions.
Types of interventions: EUS-FNAwith 22G and 25G needles.
The gold standard for the comparison of the two methods
was the result of the anatomopathological analysis of the
biopsies or resected parts of the suspicious lesions identified
by EUS-FNA or the clinical diagnosis after a follow-up of at
least 6 months.
Types of outcome measures: The efficiency indices of the
methods were evaluated, such as sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV) and
accuracy.
Information sources
Searches to select articles were carried out in electronic
databases and in reference articles related to the 22G and 25G
needle in EUS-FNA for solid pancreatic mass. The databases
used were the following: Medline, Scopus, Cochrane Central
Register of Randomized Controlled Trials/CENTRAL, Latin
American and Caribbean Health Sciences (LILACS) and
Cumulative Index to Nursing and Allied Health Literature
(CINAHL). The date of the last search in all the databases
was 03/31/2017.
Search
The search strategies used varied by database and are
specified below:
- Medline: (((((Biops* OR Cytological Techniques OR
cytolog* OR Gauge OR needle OR 22 OR 25))) AND
(((endosonography OR endoscopic ultrasonography OR
endoscopic ultrasound OR EUS OR Endoscopic Ultra-
sound-Guided Fine Needle Aspiration))))) AND random*.
- LILACS, Scopus, CINAHL, Cochrane/CENTRAL: (endo-
sonography OR endoscopic ultrasonography OR endoscopic
ultrasound) AND pancreas AND (22G OR 25G).
Study selection
The articles were initially selected by evaluation of the
titles and abstracts, followed by evaluation of the pertinence
of the complete text. This process was performed by two
independent, non-blinded reviewers. Differences were resolved
through discussion and consensus with the participation of
all authors.
Non-randomized studies and abstracts were excluded
from the meta-analysis.
Data collection process
Data were collected from absolute numbers provided directly
or from inferred information reported throughout the text.
The data were placed in 2 x 2 tables, where the true positives,
false positives, true negatives and false negatives were
separated. Each data collection process was performed by
two independent authors and reviewed by all authors. The
differences were resolved through discussion and consen-
sus among the authors. When the data were not clear in the
paper, we attempted to contact the authors by personal and
institutional email.
Data items
The criteria considered for the positivity of the methods
in the meta-analysis were the same as those established by
the authors. We did not consider the number of punctures
performed, the technique used (vacuum or not), or the
presence or not of the cytopathologist in the room (ROSE)
in the analysis.
Risk of bias in individual studies
The risk of bias was assessed through the Quality Asses-
sment of Diagnostic Accuracy Studies (QUADAS-2) and the
JADAD scale.
All non-randomized studies were excluded and were con-
sidered inadequate in the evaluation of the risk of biases of
the main test when the endoscopist knew the results of the
pathology prior to the EUS-FNA puncture. Regarding the
applicability of the methods, we evaluated whether there
was standardization of well-established and adequate criteria
to consider a puncture positive. Regarding the risk of bias
and the applicability of the gold standard examination, the
pathologist should be blinded to the type of needle used in
the positive findings.
To assess the risk of flow bias, we considered appropriate
prospective studies, the patients in which should be rando-
mized to one of the groups with examinations performed at
the same time and with similar imaging technology. We also
evaluated whether the gold standard method, the anatomo-
pathological analysis, was performed in all patients and
whether all the lesions were identified.
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Summary measures and planned methods of analysis
In the meta-analysis, we calculated the sensitivity, speci-
ficity, and negative and positive likelihood values for each
study using the Mantel-Haenszel fixed-effects method (13).
Forest plots were then generated in addition to the summary
receiver operating characteristic (sROC) curve, and calcula-
tions of the areas under the curves were performed. All the
variables were assessed in one analysis per patient. A value
of 0.1 was added to each cell in the 2x2 tables in place of
possible zero frequencies. All statistical tests were binary,
and a significance level of 5% was established. To assess
heterogeneity, the I-square test was used, where a value
greater than 50% was considered as marked heterogeneity.
The sROC curves were analyzed using the linear model
developed by Littenberg and Moses.
The software used was Meta-DiSc (version 1.4; Unit
of Clinical Biostatics, the Ramón y Cajal Hospital, Madrid,
Spain) and Review Manager (RevMan) 5.3 software (Copen-
hagen: The Nordic Cochrane Center, The Cochrane Colla-
boration, 2011).
’ RESULTS
Study selection
In the literature searches performed through the electronic
databases, 504 articles were identified (Figure 1). Of these
articles, 483 were excluded after evaluation of the title and
the abstract because they had no relation to the theme
established for this review or were duplicates. The remaining
21 articles were evaluated in their entirety.
After reading the articles, 7 studies were excluded because
they used different needles or techniques (14-20), such as 19G
needles, EUS fine-needle biopsy (EUS-FNB), or new needle
models. Thus, 14 articles were selected for the systematic
review.
Of these 14 articles that were included in the meta-analysis,
one was excluded because it was already a meta-analysis (7),
four were excluded because they were retrospective studies
(21-24), and 5 were excluded because they used both needles
in the same lesion (25-29). In the latter case, a second EUS-
FNA at the same time for the same lesion could result in
more blood contamination than the first puncture, which
could be a significant source of bias. All 4 remaining studies
consisted of randomized controlled trials and were included
in the meta-analysis (9,30-32).
Study characteristics
The four studies included in this meta-analysis provided
all the necessary data to compare the efficiency of the EUS-
FNA punctures. A total of 462 patients were evaluated, 233
of whom were punctured with 25G needles and 229 of whom
were punctured with 22G needles. All these studies were
prospective, randomized and controlled, and the patients were
separated into two homogeneous groups, with each group
evaluated by fine-needle aspiration puncture with either
22G or 25G needles. The included patients were known to
have only pancreatic masses, with varying locations within
the organ.
All four studies included in the meta-analysis included
patients with a previous diagnosis of solid pancreatic masses,
allocated by randomization in different arms for EUS-FNA
with 22G or 25G needles.
As the gold standard method, all studies used the lesion
anatomopathological evaluation or, when this was not possible,
follow-up between 6 (30) and 12 months (9).
The criteria for the definition of a solid pancreatic mass
varied among the studies. Two studies considered only the
findings of images suggestive of a solid pancreatic lesion (9,32).
The third study considered the suspected clinical picture,
associated with some direct or indirect imaging, and an
EUS demonstrating solid lesion content of at least 60% (31).
The fourth study was more generic, and any solid lesion
adjacent to the gastrointestinal tract and found by any
imaging method was punctured, including solid pancreatic
lesions. From this fourth study, only those data referring
exclusively to solid pancreatic lesions were extracted (30).
Regarding the detailed methods of the EUS-FNA per-
formed to obtain material for anatomopathological analysis,
Figure 1 - Flow chart of the studies identified with the numbers
of studies that were excluded and included in the eventual meta-
analysis.
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the studies had different techniques with respect to the use
of a vacuum, number of punctures performed, number of
oscillations performed in each puncture and the presence
of a pathologist. These methods are detailed as follows
(for more details of the studies, see Table 1):
- Vilmann P et al. 2013: used the equivalent vacuum
aspiration of 10 ml (as did the other studies) and performed
six ‘‘forward-and-backward’’ movements with the needle at
each puncture, but without the presence of a cytopathologist
in the room (30).
- Lee JK et al. 2013: used the equivalent vacuum aspiration
of 10 ml, and the stylet was present at the time of puncture;
however, a cytologist was not present in the room (9).
- Camellini L et al. 2011: kept the stylus for puncture, used
a vacuum equivalent to 10 ml, and ensured no more than
10 movements in each puncture. However, upon suspicion
of a hypervascularized lesion, the vacuum was not applied.
An anatomopathologist was present in the room to evaluate
the quality of the material obtained in each puncture and
was blinded to the needle gauge used (32).
- Siddiqui UD et al. 2009: used a vacuum by suction with
a 10-ml syringe, and a cytologist was present in the room (31).
Risk of bias within studies
All the studies had a low risk of bias with respect to patient
selection, the primary test used and the gold standard method
used. Moreover, in terms of patient flow and time, the risk
was high in 75% of the samples, as three of the four studies
had patient losses during follow-up (Figure 2A).
Regarding patient eligibility, the index test and the gold
standard method used, the risk of bias was considered low
(Figure 2B).
When the quality of the clinical trials was assessed on the
JADAD scale, they all had high scores and were considered
high-quality studies.
Analysis of results
In the per-patient analysis, four studies with a total of
462 patients were analyzed. Among these patients, 344 were
diagnosed with malignant tumors of the pancreas, corre-
sponding to 74.45% of the patients. The sensitivity of the
22G needle was 91%, with a confidence interval of 85 to
94% and a heterogeneity of 19.9% (Figure 3A). For the 25G
needle, the sensitivity was 93%, with a confidence interval
of 89-96% and heterogeneity of 0.0% (Figure 3B). There was
no statistically significant difference between the methods.
The specificity of the 22G needle was 83%, with a con-
fidence interval of 70 to 93% and heterogeneity of 81.1%
(Figure 3C). The specificity of the 25G needle was 87%,
with a confidence interval of 73-96% and heterogeneity of
41.1% (Figure 3D). Again, there was no statistically signifi-
cant difference between the methods.
The positive likelihood ratio of the 22G needle score
was 4.26, with a confidence interval of 0.43 to 41.88 and a
heterogeneity of 94.7% (Figure 4A). For the 25G needle, the
positive likelihood ratio was 4.57, with a confidence interval
of 2.08 to 10.03 and a heterogeneity of 0.0% (Figure 4B).
There was no statistically significant difference between the
methods.
The negative likelihood ratio of the 22G needle was 0.13,
with a confidence interval of 0.05 to 0.31 and heterogeneity
of 32.0% (Figure 5A). For the 25G needle, the negative like-
lihood ratio was 0.08, with a confidence interval of 0.04Ta
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to 0.15 and heterogeneity of 0.0% (Figure 5B). There was no
statistically significant difference between the methods.
The post-test probability was 93.85% for the 25G needle
and 91.30% for the 22G needle. The area under the sROC
Figure 2 - (A) Proportion of studies with high, low or inconclusive risk bias, showing only a high risk of bias in the flow and timing;
(B) Proportion of studies with biases of high, low or non-clear risk applicability. There is a low risk of applicability biases.
Figure 3 - (A) Sensitivity of EUS-FNA with the 22G needle (91%); (B) Sensitivity of EUS-FNA with the 25G needle (93%); (C) Specificity of
EUS-FNA with the 22G needle (83%); (D) Specificity of EUS-FNA with the 25G needle (87%).
Figure 4 - (A) Positive likelihood ratio of EUS-FNA 22G. For a given prevalence of 71.61%, the positive likelihood ratio of
4.26 increased the probability 4.26-fold of the result being truly positive rather than false positive, with a post-test probability of
91.3%. (B) Positive likelihood ratio of EUS-FNA with the 25G needle. For a given prevalence of 77.25%, the positive likelihood ratio
of 4.57 increased the probability 4.5-fold that the result is truly positive rather than false positive, with a post-test probability of
93.85%.
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curve was 0.9795 for the 22G needle (Figure 6A) and 0.9705
for the 25G needle (Figure 6B). There was no statistically
significant difference between them (p=0.497).
’ DISCUSSION
Summary of evidence
In our study, the sensitivity of the 25G needle was 93%,
while that for the 22G needle was 91%, and there was no
statistically significant difference between the needles.
Regarding the statistical interpretation, the positive like-
lihood ratio (+LR) of EUS-FNA with the 25G needle in our
study shows that, for a given prevalence of 77.25%, the+LR
of 4.57 increased the probability 4.5-fold that the result is
truly positive instead of being a false positive, with a post-
test probability of 93.85%. Similarly, for the 22G needle,
for a prevalence of 71.61%, the +LR of 4.26 increased this
probability 4.26-fold, with a post-test probability of 91.3%.
Meanwhile, the negative likelihood ratio (-LR) of EUS-
FNA performed with a 25G needle indicates that, for a given
prevalence of 77.25%, the -LR of 0.08 reduces the probability
of the result being truly negative rather than being a false
negative by 0.08-fold, with a post-test probability of -93.85%.
Similarly, for the 22G needle and with a prevalence of
71.61%, the -LR of 0.13 reduces that probability 0.13-fold,
with a post-test probability of -91.3%.
Moreover, a positive likelihood ratio greater than 10
provides strong evidence to confirm a positive diagnosis,
whereas a negative likelihood ratio of less than 0.1 virtually
precludes a negative diagnosis (33). Thus, the negative
likelihood ratio in this systematic review and meta-analysis
of 0.08 demonstrates that a negative result for a 25G needle is
indeed reliable.
Meanwhile, the areas under the sROC curve in the per-
patient analysis were 0.9795 for the 22G needle and 0.9705 for
the 25G needle, demonstrating good accuracy of the methods,
with no statistically significant difference between them.
The best scientific evidence currently available is from a
large meta-analysis based on 33 studies (8) that showed that
the EUS-FNA method obtained a sensitivity of 85% to 91%,
specificity of 94% to 98%, and positive predictive value of
98% to 99%, independent of the needle used for the diagnosis
of pancreatic lesions. These results are in accordance with
those derived from the present study, and they support the
recommendation to use EUS-FNA in the case of pancreatic
lesions, as EUS-FNA provides a high pre-test probability
for malignancy and negative histopathological diagnosis
(11,34,35).
Figure 5 - (A) Negative likelihood ratio of EUS-FNAwith the 22G needle. For a given prevalence of 71.61%, the negative likelihood ratio
of 0.13 reduced the probability by 0.13-fold of the result being truly negative rather than false negative, with a post-test probability of
-91.3%. (B) Negative likelihood ratio of EUS-FNA with the 25G needle. For a given prevalence of 77.25%, the negative likelihood ratio
of 0.08 reduced the probability 0.08-fold of the result being truly negative rather than false negative, with a post-test probability of
-93.85%.
Figure 6 - (A) sROC curve for EUS-FNA with the 22G needle. Area under the curve of 97.95%. (B) sROC curve for EUS-FNA with the 25G
needle. Area under the curve of 97.05%.
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Madhoun et al. (7) published the most recent meta-analysis
on this subject in 2013, and of the eight meta-analysis, three
were retrospective, five were prospective and only three were
randomized and double blind. Nevertheless, the authors
found a sensitivity and specificity of 85% and 100% for the
22G needle, respectively. For the 25G needle, the sensitivity
values were 93% and 97%, respectively. Moreover, they
proved in a linear bivariate analysis that the 25G needle is
more sensitive than the 22G needle (p=0.0003), although the
needles had comparable specificity (p=0.97).
The meta-analysis by Madhoun et al. was based on retro-
spective studies. Despite reporting a heterogeneity of 0.0%,
the results were polarized by the study by Yusuf et al., which
was also a retrospective study. The allocation of cases to the
needles was made based on the availability of the needles.
During the initial phase, only 22G needles were available,
while 25G needles were used following the initial phase (21).
We believe that the cases collected in retrospective studies or
the cases in which the lesion was punctured with the two
needles directly interfered with this result. For example, the
accuracy of one puncture performed after another could be
reduced due to the aspiration of a large quantity of red blood
cells, especially if the 22G needle was used in the second
puncture. In contrast, our meta-analysis involved only
randomized controlled trials, with heterogeneities of 0.0%
and 19.9% when referring to the sensitivity of the 25G and
22G needles, respectively. In accordance with our results,
in 2013, Affoler et al. published a more extensive systematic
review that included 19G needles and subgroup analyses
(10). This analysis showed no statistically significant differ-
ence between needle calibers in the diagnosis of pancreatic
lesions, with a sensitivity of 91% for the 25G needle and 78%
for the 22G needle. Despite this result, a high heterogeneity
for sensitivity was found (I2=85.1%), making any compara-
tive analysis between the needles impossible. This is the first
meta-analysis comparing such needles that is based only
on uniform studies and with a high methodological value.
After the statistical analysis, we verified that there was no
statistically significant difference in the diagnostic capacity
for malignancy of the solid pancreatic masses between the
two needles.
As has been noted in several other studies, we found that
the larger drilling area of the 22G needle did not translate
into samples of higher volume or quality. This conclusion
reinforces the idea that efforts to optimize diagnosis by EUS-
FNA should perhaps focus on other factors. Moreover, the
success of a larger-caliber needle is limited by the anatomy of
the target lesion, particularly in pancreatic head and uncinate
lesions (29).
The discrepancy in the literature shows that needle selection
is a complex process that depends on several factors, such
as lesion morphology and location, presence of a cytopatho-
logist in the room, and preferences of the endoscopist (11).
Regarding the possible biases of our study, the QUADAS-2
analysis indicated a high variance in follow-up time and
patient flow. For example, not all the patients in the included
studies were surgically operated on, and anatomopathologi-
cal analysis of the surgical specimens as a method of com-
parison was therefore not performed. Moreover, some of the
studies had a follow-up time of six months after diagnosis,
which may not necessarily be a sufficient duration to evaluate
the long-term disease course.
It should be emphasized that this is a pure meta-analysis,
with all the studies involved being randomized, controlled
and blind clinical trials of high methodological and statistical
value, a type of analysis that has not yet been published on
this subject.
This systematic review and meta-analysis did not demon-
strate a statistically significant difference between 22G and
25G needles in EUS-FNA for the diagnosis of solid pancreatic
lesions.
Therefore, the choice of needle for use in EUS-FNA for
solid pancreatic masses must be determined by the physi-
cian, who should carefully study the different variables that
will affect the tissue sampling, such as material availability,
transgastric or transduodenal puncture, size and location
of the lesion, and whether the purpose is diagnostic or
therapeutic.
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